Lipid management and newer therapies

Rakhi talks to Antonio about newer therapies for lipid management, incliseran and bemepdoic acid. They discuss their place in therapy and how they may be initiated in primary care. This is the final part of our three-part series. Antonio Ochoa-Ferraro: Consultant Pharmacist, Inherited Metabolic Disorders; University Hospitals of Birmingham Rakhi Aggarwal: Primary Care Lead, Medicines Use and Safety; NHS SPS Useful links Cholesterol and Cholesterol levels https://www.heartuk.org.uk/cholesterol/overview NICE guidance Inclisiran: https://www.nice.org.uk/guidance/TA733 Bempedopic acid with ezetimibe: https://www.nice.org.uk/guidance/ta694 NHS England summary of national guidance for lipid management https://www.england.nhs.uk/aac/publication/summary-of-national-guidance-for-lipid-management/ NHS Birmingham and Solihull ICB procurement & prescribing of inclisiran https://www.birminghamandsurroundsformulary.nhs.uk/docs/files/Procurement%20and%20Prescribing%20of%20Inclisiran.pdf?UNLID=93161104220252141045 Novartis inclisiran resources https://www.pro.novartis.com/uk-en/medicines/cardio-metabolic/leqvio/resources Open Access Articles Harnessing RNA Interference for Cholesterol Lowering: The Bench-to-Bedside Story of Inclisiran https://pubmed.ncbi.nlm.nih.gov/38456415/ Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial https://pubmed.ncbi.nlm.nih.gov/38753448/ Bempedoic Acid for Prevention of Cardiovascular Events in People With Obesity: A CLEAR Outcomes Subset Analysis https://pubmed.ncbi.nlm.nih.gov/39921511/ Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society https://pubmed.ncbi.nlm.nih.gov/23956253/